Table 5: Changes in clinical and radiographic parameters over time.

Month Group

M0 (Baseline)

M12

M24

M36

M48

M60

M72

M84

M96

NS

                

 

K/L-II’H’†

            

 

THR-M85

(M84-M86)

 

PW-VAS

41 (39-42)

43 (41-45)

47 (46-48)

51 (50-52)

55 (54-56)

59 (58-60)

65 (64-66)

74 (73-75)

 

WOMAC-C

32 (31-33)

34 (31-36)

37 (36-38)

41 (40-42)

45 (44-46)

50 (49-51)

56 (55-57)

64 (64-65)

 

TB-BMD

1.5 (1.4-1.6)

1.5 (1.4-1.6)

1.4 (1.3-1.5)

1.3 (1.2-1.4)

1.2 (1.1-1.3)

1.0 (0.9-1.1)

0.8 (0.7-0.9)

0.5 (0.4-0.6)

 

mJSW

4.4 (4.1-4.7)

3.9 (3.7-4.1)

3.4 (3.3-3.5)

2.6 (2.4-2.85)

2.3 (2.2-2.4)

1.7 (1.6-1.8)

1.1 (1.0-1.2)

0.4 (0.4-0.5)

 

K/L-I’I’†

            

THR-M73

(M72-M74)

  

 

PW-VAS

43 (42-44)

46 (45-48)

50 (49-51)

55 (54-56)

61 (60-62)

67 (66-68)

74 (74-75)

 

 

WOMAC-C

33 (32-35)

36 (35-38)

40 (39-41)

45 (44-46)

51 (50-52)

57 (56-58)

63 (62-64)

 

 

TB-BMD

1.4 (1.3-1.5)

1.3 (1.2-1.4)

1.2 (1.1-1.3)

1.1 (1.0-1.2)

0.9 (0.8-1.0)

0.7 (0.6-0.8)

0.5 (0.4-0.6)

 

 

mJSW

4.3 (3.8-4.7)

3.8 (3.7-4.0)

3.3 (3.1-3.3)

2.4 (2.3-2.65)

2.0 (1.9-2.1)

1.2 (1.1-1.3)

0.5 (0.5-0.6)

 

 

K/L-II’A’†

          

THR-M61

(M60-M62)

    

 

PW-VAS

45 (43-47)

50 (49-52)

55 (55-57)

60 (58-62)

65 (64-66)

70 (69-71)

 

 

 

WOMAC-C

36 (35-37)

40 (39-42)

45 (45-47)

50 (49-51)

56 (55-57)

62 (61-63)

 

 

 

TB-BMD

1.3 (1.2-1.4)

1.1 (1.0-1.2)

0.9 (0.8-1.0)

0.7 (0.6-0.7)

0.5 (0.4-0.6)

0.3 (0.3-0.4)

 

 

 

mJSW

4.2 (3.7-4.7)

3.6 (3.5-3.9)

3.0 (2.9-3.1)

2.2 (2.06-2.4)

1.5 (1.4-1.6)

0.5 (0.4-0.6)

 

 

 

K/L-III’H’†

          

THR-M61

(M60-M61)

    

 

PW-VAS

48 (47-49)

48 (47-50)

52 (51-53)

57 (58-61)

63 (63-64)

70 (69-70)

 

 

 

WOMAC-C

38 (37-39)

38 (37-40)

42 (41-43)

48 (51-54)

54 (53-55)

62 (61-63)

 

 

 

TB-BMD

1.4 (1.3-1.5)

1.3 (1.2-1.4)

1.1 (1.0-1.2)

0.9 (0.7-1.0)

0.5 (0.4-0.6)

0.3 (0.3-0.4)

 

 

 

mJSW

3.6 (3.2-4.0)

3.1 (2.9-3.3)

2.5 (2.4-2.6)

1.6 (1.45-1.76)

1.1 (1.0-1.2)

0.4 (0.4-0.5)

 

 

 

K/L-III’I’†

        

THR-M49

(M48-M50)

      

 

PW-VAS

50 (49-52)

52 (51-54)

56 (55-58)

62 (60-63)

70 (69-71)

 

 

 

 

WOMAC-C

41 (39-42)

42 (41-44)

45 (44-46)

52 (51-53)

62 (61-64)

 

 

 

 

TB-BMD

1.3 (1.2-1.4)

1.1 (1.0-1.2)

0.9 (0.8-1.0)

0.7 (0.7-0.8)

0.4 (0.4-0.5)

 

 

 

 

mJSW

3.5 (3.1-3.9)

2.9 (2.7-3.2)

2.1 (2.0-2.4)

1.2 (1.1-1.45)

0.4 (0.4-0.5)

 

 

 

 

K/L-III’A’†

      

THR-M37

(M36-M38)

        

 

PW-VAS

52 (51-53)

54 (53-57)

60 (59-61)

72 (71-73)

 

 

 

 

 

WOMAC-C

43 (43-45)

45 (43-47)

52 (50-54)

64 (62-66)

 

 

 

 

 

TB-BMD

1.2 (1.1-1.3)

0.9 (0.9-1.0)

0.6 (0.6-0.7)

0.3 (0.3-0.4)

 

 

 

 

 

mJSW

3.4 (3.0-3.8)

2.6 (2.5-2.8)

1.7 (1.7-1.9)

0.4 (0.3-0.5)

 

 

 

 

 

MMW-HA

                

 

K/L-II’H’†

                

 

PW-VAS

41 (39-42)

18 (17-19)#

23 (22-24)#

28 (27-29)#

33 (32-35)*

40 (39-41)

50 (49-51)

60 (61-63)

75 (74-75)

WOMAC-C

31 (31-33)

9 (8-10)#

14 (13-15)#

19 (18-20)#

24 (23-26)*

31 (30-32)

40 (39-41)

50 (51-53)

65 (64-65)

TB-BMD

1.5 (1.4-1.6)

1.5 (1.4-1.6)

1.5 (1.4-1.6)

1.4 (1.5-1.7)

1.3 (1.6-1.8)

1.2 (1.6-1.8)

1.1 (1.4-1.6)

1.0 (0.9-1.1)

0.8 (0.7-0.9)

mJSW

4.4 (3.9-4.9)

4.0 (3.9-4.1)

3.6 (3.5-3.7)

3.2 (3.1-3.3)

2.8 (2.7-2.9)

2.4 (2.3-2.5)

2.0 (1.9-2.1)

1.5 (1.4-1.6)

1.0 (0.9-1.1)

K/L-II’I’†

            

 

  

THR-M97

(M96-M98)

PW-VAS

43 (41-45)

20 (19-210)#

25 (24-26)#

30 (29-31)#

36 (35-37)

44 (43-45)

53 (52-54)

63 (62-64)

75 (74-75)

WOMAC-C

34 (32-36)

10 (9-11)#

16 (15-17)#

20 (19-21)#

26 (25-27)

34 (33-35)

43 (42-44)

53 (52-54)

65 (64-65)

TB-BMD

1.4 (1.3-1.5)

1.4 (1.3-1.5)

1.4 (1.4-1.6)

1.3 (1.5-1.7)

1.2 (1.6-1.8)

1.1 (1.0-1.2)

1.0 (0.9-1.1)

0.8 (0.7-0.9)

0.5 (0.4-0.5)

mJSW

4.3 (3.8-4.8)

3.9 (3.8-4.0)

3.4 (3.3-3.5)

2.9 (2.7-3.1)

2.4 (2.3-2.5)

1.9 (1.8-2.0)

1.4 (1.3-1.5)

0.9 (0.8-1.0)

0.4 (0.4-0.5)

K/L-II’A’†

            

THR-M78

(M78-M79)

  

 

PW-VAS

45 (43-47)

26 (25-27)#

34 (33-35)#

42 (41-43)*

51 (50-52)

61 (60-62)

71 (70-72)

 

 

WOMAC-C

36 (34-37)

15 (24-16)#

25 (24-26)#

33 (32-34)*

42 (41-43)

52 (51-53)

63 (62-64)

 

 

TB-BMD

1.3 (1.1-1.3)

1.2 (1.1-1.3)

1.1 (1.0-1.2)

1.0 (0.9-1.1)

0.9 (0.8-1.0)

0.7 (0.6-0.8)

0.5 (0.4-0.6)

 

 

mJSW

4.2 (3.7-4.7)

3.7 (3.7-4.0)

3.2 (3.2-3.4)

2.7 (2.6-2.8)

2.1 (2.0-2.2)

1.5 (1.4-1.6)

0.8 (0.7-0.9)

 

 

K/L-III’H’†

            

THR-M73

(M72-M74)

  

 

PW-VAS

48 (46-51)

27 (26-27)#

36 (35-37)#

44 (43-45)*

53 (52-54)

63 (62-64)

74 (73-75)

 

 

WOMAC-C

38 (36-40)

18 (17-19)#

27 (26-28)#

35 (34-36)*

44 (43-45)

54 (53-55)

64 (63-65)

 

 

TB-BMD

1.4 (1.3-1.5)

1.4 (1.2-1.4)

1.3 (1.2-1.4)

1.2 (1.1-1.36)

1.1 (1.0-1.1)

0.9 (0.8-0.9)

0.6 (0.5-0.6)

 

 

mJSW

3.6 (3.1-4.1)

3.2 (3.0-3.4)

2.7 (2.7-2.8)

2.2 (2.1-2.3)

1.6 (0.7-0.9)

1.0 (1.0-1.1)

0.4 (0.4-0.5)

 

 

K/L-III’I’†

          

THR-M61

(M60-M62)

    

 

PW-VAS

50 (49-52)

32 (31-33)#

42 (41-43)*

54 (53-55)

65 (64-66)

73 (72-74)

 

 

 

WOMAC-C

41 (39-43)

23 (22-24)#

33 (32-34)*

45 (44-46)

56 (55-57)

63 (62-64)

 

 

 

TB-BMD

1.3 (1.2-1.4)

1.4 (1.2-1.4)

1.5 (1.3-1.5)

1.6 (1.4-1.6)

1.6 (1.4-1.6)

0.5 (0.4-0.6)

 

 

 

mJSW

3.5 (3.0-4.0)

2.9 (2.8-3.1)

2.4 (2.3-2.5)

1.8 (1.6-2.0)

0.8 (0.7-0.9)

0.5 (0.5-0.6)

 

 

 

K/L-III ‘A’†

        

THR-M49

(M48-M50)

      

 

PW-VAS

53 (52-55)

38 (37-39)#

53 (52-54)

63 (61-64)

73 (72-74)

 

 

 

 

WOMAC-C

43 (41-45)

29 (28-30)#

44 (43-45)

54 (53-55)

64 (62-64)

 

 

 

 

TB-BMD

1.2 (1.1-1.3)

1.1 (1.0-1.2)

1.0 (0.9-1.1)

0.8 (0.7-0.9)

0.5 (0.4-0.5)

 

 

 

 

mJSW

3.4 (3.0-3.8)

2.8 (2.7-2.9)

2.1 (2.0-2.2)

1.3 (1.2-1.5)

0.5 (0.4-0.5)

 

 

 

 

CS

 

 

 

 

 

 

 

 

 

K/L-II’H’†

 

 

 

 

 

 

 

THR-M85

(M84-M86)

 

PW-VAS

41 (40-42)

19 (18-20) #

27 (26-28)#

35 (34-36)*

44 (43-45)

54 (53-55)

64 (63-65)

75 (74-75)

 

WOMAC-C

32 (31-33)

9 (8-11) #

17 (16-18)#

25 (24-26)*

34 (33-35)

44 (43-45)

54 (53-55)

65 (64-65)

 

TB-BMD

1.5 (1.4-1.6)

1.5 (1.4-1.6)

1.4 (1.3-1.5)

1.3 (1.2-1.4)

1.2 (1.1-1.2)

1.0 (0.9-1.1)

0.8 (0.7-0.9)

0.5 (0.4-0.6)

 

mJSW

4.4 (4.0-4.9)

3.9 (3.7-4.1)

3.4 (3.3-3.5)

2.8(2.7-2.9)

2.3 (2.2-2.4)

1.8 (1.7-1.9)

1.1 (1.0-1.2)

0.4 (0.4-0.5)

 

K/L-II-‘I’†

 

 

 

 

 

 

THR-M73

(M72-M74)

 

 

PW-VAS

43 (41-45)

25 (23-27)#

34 (32-37)*

43 (42-45)

53 (52-54)

63 (62-64)

74 (73-75)

 

 

WOMAC-C

34 (32-36)

15 (13-17)#

25 (23-27)*

34 (33-36)

44 (43-45)

54 (53-55)

65 (64-65)

 

 

TB-BMD

1.4 (1.3-1.5)

1.3 (1.2-1.4)

1.2 (1.1-1.3)

1.1 (1.0-1.2)

1.0 (0.9-1.1)

0.8 (0.7-0.9)

0.5 (0.4-0.6)

 

 

mJSW

4.3 (3.8-4.8)

3.8 (3.6-4.1)

3.3 (3.2-3.4)

2.5 (2.4-2.7)

2.0 (2.1-2.2)

1.2 (1.1-1.3)

0.4 (0.4-0.5)

 

 

K/L-III-‘H’†

 

 

 

 

 

THR-M61

(M60-M62)

 

 

 

PW-VAS

48 (47-49)

36 (35-37)#

41 (40-42)*

51 (50-52)

62 (61-63)

74 (73-75)

 

 

 

WOMAC-C

38 (37-39)

26 (25-28)#

31 (30-32)*

41 (40-42)

52 (51-53)

64 (63-65)

 

 

 

TB-BMD

1.4 (1.3-1.5)

1.3 (1.2-1.4)

1.2 (1.1-1.3)

1.0 (0.9-1.1)

0.8 (0.7-0.9)

0.5 (0.4-0.5)

 

 

 

mJSW

3.6 (3.1-4.1)

3.1 (3.0-3.2)

2.5 (2.4-2.6)

1.8 (1.7-1.9)

1.1 (1.0-1.2)

0.4 (0.4-0.5)

 

 

 

K/L-III-‘I’†

 

 

 

 

THR-M49

(M48-M50)

 

 

 

 

PW-VAS

50 (48-52)

40 (39-43)#

51 (50-53)

62 (61-63)

74 (73-75)

 

 

 

 

WOMAC-C

41 (39-42)

31 (29-33)#

42 (51-54)

 53 (52-54)

65 (64-65)

 

 

 

 

TB-BMD

1.3 (1.2-1.4)

1.0 (0.9-1.1)

0.8 (0.8-1.0)

0.6 (0.6-0.8)

0.4 (0.4-0.5)

 

 

 

 

mJSW

3.5 (3.0-4.0)

2.9 (2.7-3.1)

2.1 (2.1-2.3)

1.3 (1.2-1.4)

0.5 (0.4-0.6)

 

 

 

 

PW - Pain at walking by VAS; WOMAC-C - WOMAC function scale; NS - control group; CS - IA-CS group; MMW-HA (Euflexxa group); †- Each study subgroup included 25 subjects; III/II -radiographic grade III /II -according to Kellgren-Lawrence; ‘A’; ‘I’; ‘H’ - atrophic, normotrophic, hypertrophic patterns; *- MCII responses. #- OARSI responses.

Changes in uctx-II levels over time for the different radiographic grades and patterns, under the different treatments are presented in Figure 10 and 10-a.